259 related articles for article (PubMed ID: 7559193)
21. [New pathogens and mode of action of azithromycin: Toxoplasma gondii].
Derouin F
Pathol Biol (Paris); 1995 Jun; 43(6):561-4. PubMed ID: 8539083
[TBL] [Abstract][Full Text] [Related]
22. Study of treatment of congenital Toxoplasma gondii infection in rhesus monkeys with pyrimethamine and sulfadiazine.
Schoondermark-van de Ven E; Galama J; Vree T; Camps W; Baars I; Eskes T; Meuwissen J; Melchers W
Antimicrob Agents Chemother; 1995 Jan; 39(1):137-44. PubMed ID: 7695295
[TBL] [Abstract][Full Text] [Related]
23. Influence of antimicrobial agents on replication and stage conversion of Toxoplasma gondii.
Gross U; Pohl F
Curr Top Microbiol Immunol; 1996; 219():235-45. PubMed ID: 8791704
[No Abstract] [Full Text] [Related]
24. The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine.
Araujo FG; Lin T; Remington JS
J Infect Dis; 1993 Feb; 167(2):494-7. PubMed ID: 8421189
[TBL] [Abstract][Full Text] [Related]
25. In vitro effects of sulfadiazine and its metabolites alone and in combination with pyrimethamine on Toxoplasma gondii.
Schoondermark-van de Ven E; Vree T; Melchers W; Camps W; Galama J
Antimicrob Agents Chemother; 1995 Mar; 39(3):763-5. PubMed ID: 7793889
[TBL] [Abstract][Full Text] [Related]
26. Treatment of experimental Toxoplasma gondii infection by clarithromycin-based combination therapy with minocycline or pyrimethamine.
Alder J; Hutch T; Meulbroek JA; Clement JC
J Acquir Immune Defic Syndr (1988); 1994 Nov; 7(11):1141-8. PubMed ID: 7932081
[TBL] [Abstract][Full Text] [Related]
27. Recombinant bactericidal/permeability-increasing protein (rBPI21) in combination with sulfadiazine is active against Toxoplasma gondii.
Khan AA; Lambert LH; Remington JS; Araujo FG
Antimicrob Agents Chemother; 1999 Apr; 43(4):758-62. PubMed ID: 10103177
[TBL] [Abstract][Full Text] [Related]
28. Experimental evaluation of combined prophylaxis against murine pneumocystosis and toxoplasmosis.
Brun-Pascaud M; Chau F; Simonpoli AM; Girard PM; Derouin F; Pocidalo JJ
J Infect Dis; 1994 Sep; 170(3):653-8. PubMed ID: 8077724
[TBL] [Abstract][Full Text] [Related]
29. Pravastatin and Simvastatin Pretreatment in Combination with Pyrimethamine and Sulfadiazine Reduces Infection Process of Toxoplasma gondii Tachyzoites (RH Strain) in HeLa Cells.
Sanfelice RADS; da Silva SS; Bosqui LR; Machado LF; Miranda-Sapla MM; Panagio LA; Navarro IT; Conchon-Costa I; Pavanelli WR; Almeida RS; Costa IN
Acta Parasitol; 2019 Sep; 64(3):612-616. PubMed ID: 31286354
[TBL] [Abstract][Full Text] [Related]
30. Effect of pyrimethamine and sulfadiazine on the fine structure and multiplication of Toxoplasma gondii in cell cultures.
Sheffield HG; Melton ML
J Parasitol; 1975 Aug; 61(4):704-12. PubMed ID: 1165554
[TBL] [Abstract][Full Text] [Related]
31. Lack of therapeutic effect of colchicine on murine toxoplasmosis.
Aguirre-Cruz L; Sotelo J
J Parasitol; 1998 Feb; 84(1):163-4. PubMed ID: 9488356
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of epiroprim (Ro11-8958), a new dihydrofolate reductase inhibitor, in the treatment of acute Toxoplasma infection in mice.
Martinez A; Allegra CJ; Kovacs JA
Am J Trop Med Hyg; 1996 Mar; 54(3):249-52. PubMed ID: 8600759
[TBL] [Abstract][Full Text] [Related]
33. In vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin against Toxoplasma gondii.
Araujo FG; Shepard RM; Remington JS
Eur J Clin Microbiol Infect Dis; 1991 Jun; 10(6):519-24. PubMed ID: 1655433
[TBL] [Abstract][Full Text] [Related]
34. Toxoplasma gondii: in vitro and in vivo activities of the hydroxynaphthoquinone 2-hydroxy-3-(1'-propen-3-phenyl)-1,4-naphthoquinone alone or combined with sulfadiazine.
Ferreira RA; Oliveira AB; Ribeiro MF; Tafuri WL; Vitor RW
Exp Parasitol; 2006 Jun; 113(2):125-9. PubMed ID: 16458300
[TBL] [Abstract][Full Text] [Related]
35. Effect of deferoxamine alone and combined with pyrimethamine on acute toxoplasmosis in mice.
Mahmoud MS
J Egypt Soc Parasitol; 1999; 29(3):791-803. PubMed ID: 12561919
[TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo evaluation of kojic acid against Toxoplasma gondii in experimental models of acute toxoplasmosis.
Montazeri M; Emami S; Asgarian-Omran H; Azizi S; Sharif M; Sarvi S; Rezaei F; Sadeghi M; Gohardehi S; Daryani A
Exp Parasitol; 2019 May; 200():7-12. PubMed ID: 30904693
[TBL] [Abstract][Full Text] [Related]
37. Determination of parasitic burden in the brain tissue of infected mice in acute toxoplasmosis after treatment by fluconazole combined with sulfadiazine and pyrimethamine.
Sina S; Mohammad JM; Reza S; Anita M; Soudabeh E; Hadi M
Eur J Med Res; 2021 Jun; 26(1):65. PubMed ID: 34193287
[TBL] [Abstract][Full Text] [Related]
38. In vivo and in vitro activity of roxithromycin against Toxoplasma gondii in mice.
Luft BJ
Eur J Clin Microbiol; 1987 Aug; 6(4):479-81. PubMed ID: 3665901
[TBL] [Abstract][Full Text] [Related]
39. [The evaluation of the efficacy of azithromycin and pyrimethamine used alone or in combination in the treatment of an experimental infection in mice by Toxoplasma gondii].
Braz LM; Di Pietro AO; Amato Neto V; França FO
Rev Soc Bras Med Trop; 1999; 32(4):401-3. PubMed ID: 10495670
[TBL] [Abstract][Full Text] [Related]
40. Toxoplasma gondii: effects of Artemisia annua L. on susceptibility to infection in experimental models in vitro and in vivo.
de Oliveira TC; Silva DA; Rostkowska C; Béla SR; Ferro EA; Magalhães PM; Mineo JR
Exp Parasitol; 2009 Jul; 122(3):233-41. PubMed ID: 19389400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
